Mobile

A study looking at the immune response in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002808-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective for this study is to analyse the impact of inhibition of viral replication by interferon-free therapy consisting of Sofosbuvir and Daclatasvir (±Ribavirin) on the phenotype and function of the innate immune cells and HCV-specific T-cells, in treatment-naive or previously relapsed chronic hepatitis C patients with GT-1, -3 or -4 infection.

Critère d'inclusion

  • Chronic hepatitis C

Liens